Results 91 to 100 of about 273 (101)
Therapeutic developments for tuberculosis and nontuberculous mycobacterial lung disease. [PDF]
Nat Rev Drug DiscovDartois V, Dick T.
europepmc +1 more source
Advances and prospects for treatment strategies of drug-resistant tuberculosis: a review. [PDF]
GMS Hyg Infect ControlMichalik M +7 more
europepmc +1 more source
A Comprehensive Review of Genetic Mechanisms of <i>Mycobacterium tuberculosis</i> Resistance to Injectable Agents, Second-Line Drugs, and Novel Therapeutics. [PDF]
Infect Drug ResistRoshdi Maleki M.
europepmc +1 more source
Antibacterials with Novel Chemical Scaffolds in Clinical Development. [PDF]
DrugsHeimann D +3 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
The Journal of Clinical Pharmacology
AbstractDelpazolid (LCB01‐0371) is a novel oxazolidinone derivative with a good safety profile for treating gram‐positive pathogenic infections such as Mycobacterium abscessus, a highly pathogenic drug‐resistant Mycobacterium. In this study, we evaluated the pharmacokinetics (PK) and pharmacodynamics (PD) of delpazolid after 14 days of multiple oral ...
Sang Min, Lee +6 more
openaire +2 more sources
AbstractDelpazolid (LCB01‐0371) is a novel oxazolidinone derivative with a good safety profile for treating gram‐positive pathogenic infections such as Mycobacterium abscessus, a highly pathogenic drug‐resistant Mycobacterium. In this study, we evaluated the pharmacokinetics (PK) and pharmacodynamics (PD) of delpazolid after 14 days of multiple oral ...
Sang Min, Lee +6 more
openaire +2 more sources
Delpazolid. Oxazolidinone antibiotic, Treatment of tuberculosis
Drugs of the Future, 2018null Kaul, G. +2 more
openaire +1 more source